Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 24
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Corcept Therapeutics Inc
CORT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$85.86
-21.64
-20.13%
Ult. Agg.: Oct 23, 7:41 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Corcept Therapeutics Financials
Corcept Therapeutics (CORT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know
Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
Mohd Haider
PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est
Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
Benzinga Newsdesk
PRO
Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 24.14 percent increase over earnings of $0.29 per
Benzinga Newsdesk
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk
Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortfall, and raised 2026 sales outlook.
Vandana Singh
PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $900.000M-$1.000B to $950.000M-$1.050B vs $941.180M Est
Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $900.000 million-$1.000 billion to $950.000 million-$1.050 billion vs $941.180 million estimate.
Benzinga Newsdesk
PRO
Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 276.47 percent decrease over earnings of $0.17 per share
Benzinga Newsdesk
